Live Breaking News & Updates on Encouraging Clinical Activity
Stay updated with breaking news from Encouraging clinical activity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(0) Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021 BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24 th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021). The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical activity even at lower dose levels in heavily pre-treated relapsed / refractory (R/R) CD30+ lymphoma patients. The dataset includes three patients dosed at the lowest dosing level (4 × 10 ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent . SpringWorks Therapeutics, Inc.February 25, 2021 GMT - Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled - - - Continued to Strengthen Nirogacestat Patent Portfolio - - Multiple Data Readouts Expected in 2021 Across Pipeline, Including Topline Data from Phase 3 DeFi Trial in Desmoid Tumors and Initial Nirogacestat BCMA Combination Data - ADVERTISEMENT - Ended 2020 with $561.8 Million in Cash, Cash Equivalents and Marketable Securities - ....